Altered Expression of p53, p21WAF1, p16, Rb, Smad4 and c-erbB-2 in Resected Pancreatic Ductal Adenocarcinoma
°À±°æ, ±è¿ìÈ£,
¼Ò¼Ó »ó¼¼Á¤º¸
°À±°æ ( Kang Yun-Kyung )
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¹éº´¿ø º´¸®Çб³½Ç
±è¿ìÈ£ ( Kim Woo-Ho )
¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
KMID : 0357920020360060382
Abstract
Background: Our aim was to undertake a comprehensive analysis of the expression of key molecular markers in a series of pancreatic ductal adenocarcinomas and to determine their association with clinicopathologic variables.
Methods: By using immunohistochemical staining, we examined the expressions of five tumor suppressor genes (p53, p21WAF1, p16, Rb, Smad4) and a growth factor receptor (c-erbB-2) in 52 surgically resected pancreatic ductal adenocarcinomas.
Results: Abnormal nuclear overexpression of p53 was noted in 28/52 (53.8%) cases. Total loss of p21WAF1, p16, Rb, and Smad4 was detected in 15/52 (28.8%), 33/52 (63.5%), 4/52 (7.7%), and 26/52 (50%) cases, respectively. Overexpression of c-erbB-2 was noted in 21/52 (40.4%) cases. Forty-nine (94.2%) cases revealed aberration of at least one of the markers examined. There was a positive correlation between p53 and c-erbB-2 overexpression (p<0.05). Among the examined genes, overexpression of c-erbB-2 was found to have a positive relationship with the tumor stage (p<0.05). There was also a significant correlation between the histologic grade and the number of abnormally expressed genes per tumor (p<0.05).
Conclusion: Among the various tumor-associated proteins evaluated in this study, c-erbB-2 could have the most likely clinical implication.
Å°¿öµå
Carcinoma;Pancreatic Ductal-GenesTumor suppressor-Receptor;erbB-2;Immunohistochemistry
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸